← All trials
NCT06410833
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 9, 2024
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2026
- First posted
- May 13, 2024
- Last posted
- May 16, 2024
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Chongqing Medical UniversityCollaborator
- Fudan UniversityCollaborator
- Capital Medical UniversityCollaborator
- Shengjing HospitalCollaborator
- Shenzhen UniversityCollaborator
- Central South UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jinlin UniversityCollaborator
- Chinese Academy of Medical SciencesSponsor investigator
- Qingdao UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Nanjing Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.